PURPOSE: To compare the prevalence of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castrate-resistant prostate cancer (mCRPC) and assess the impact of mutations on progression to castration resistance and overall survival. METHODS: Targeted sequencing of germline DNA from 704 men (221 at the time of mHSPC and 483 at the time of mCRPC) enrolled in two advanced prostate cancer registries at Mayo Clinic between 2003 and 2013 was performed for 21 predisposition genes. Frequencies of pathogenic mutations were compared in patients and reference controls to identify genes enriched in metastatic prostate cancer. Multivariable Cox proportional hazards regression was used to identify predictors of progression to mCRPC and overall survival. RESULTS: Sixty-eight germline mutations in 12 genes were identified in 66 men (9.4%). Mutations in ATM, BRCA2, CHEK2, FANCM, and TP53 were significantly enriched (odds ratio greater than 2.0) in the metastatic cohorts compared with reference controls. The frequency of germline mutations was similar for patients with mHSPC and mCRPC (11.8% v 8.3%; P = .16). The median time to progression from mHSPC to mCRPC was 23.1 and 32.5 months for patients with and without mutations, respectively (P = .96). Although older age at diagnosis, Gleason score greater than 7, elevated alkaline phosphatase level, and high volume of disease were associated with shorter duration of progression to mCRPC and poor overall survival, mutation status was not (progression to mCRPC hazard ratio, 0.81; 95% CI, 0.61 to 1.09; P = .17; overall survival hazard ratio, 1.00; 95% CI, 0.75 to 1.34; P = .98). CONCLUSION: Similarly elevated rates of germline predisposition gene mutations in mHSPC and mCRPC suggest that germline genetic testing may help to guide medical management for all patients with advanced metastatic prostate cancer. Mutation status was not associated with shorter progression to mCRPC or poor overall survival.
PURPOSE: To compare the prevalence of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castrate-resistant prostate cancer (mCRPC) and assess the impact of mutations on progression to castration resistance and overall survival. METHODS: Targeted sequencing of germline DNA from 704 men (221 at the time of mHSPC and 483 at the time of mCRPC) enrolled in two advanced prostate cancer registries at Mayo Clinic between 2003 and 2013 was performed for 21 predisposition genes. Frequencies of pathogenic mutations were compared in patients and reference controls to identify genes enriched in metastatic prostate cancer. Multivariable Cox proportional hazards regression was used to identify predictors of progression to mCRPC and overall survival. RESULTS: Sixty-eight germline mutations in 12 genes were identified in 66 men (9.4%). Mutations in ATM, BRCA2, CHEK2, FANCM, and TP53 were significantly enriched (odds ratio greater than 2.0) in the metastatic cohorts compared with reference controls. The frequency of germline mutations was similar for patients with mHSPC and mCRPC (11.8% v 8.3%; P = .16). The median time to progression from mHSPC to mCRPC was 23.1 and 32.5 months for patients with and without mutations, respectively (P = .96). Although older age at diagnosis, Gleason score greater than 7, elevated alkaline phosphatase level, and high volume of disease were associated with shorter duration of progression to mCRPC and poor overall survival, mutation status was not (progression to mCRPC hazard ratio, 0.81; 95% CI, 0.61 to 1.09; P = .17; overall survival hazard ratio, 1.00; 95% CI, 0.75 to 1.34; P = .98). CONCLUSION: Similarly elevated rates of germline predisposition gene mutations in mHSPC and mCRPC suggest that germline genetic testing may help to guide medical management for all patients with advanced metastatic prostate cancer. Mutation status was not associated with shorter progression to mCRPC or poor overall survival.
Authors: Mark M Pomerantz; Sandor Spisák; Li Jia; Angel M Cronin; Istvan Csabai; Elisa Ledet; A Oliver Sartor; Irene Rainville; Edward P O'Connor; Zachary T Herbert; Zoltan Szállási; William K Oh; Philip W Kantoff; Judy E Garber; Deborah Schrag; Adam S Kibel; Matthew L Freedman Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Matti Annala; Werner J Struss; Evan W Warner; Kevin Beja; Gillian Vandekerkhove; Amanda Wong; Daniel Khalaf; Irma-Liisa Seppälä; Alan So; Gregory Lo; Rahul Aggarwal; Eric J Small; Matti Nykter; Martin E Gleave; Kim N Chi; Alexander W Wyatt Journal: Eur Urol Date: 2017-03-01 Impact factor: 20.096
Authors: Bertrand Tombal; Michael Borre; Per Rathenborg; Patrick Werbrouck; Hendrik Van Poppel; Axel Heidenreich; Peter Iversen; Johan Braeckman; Jiri Heracek; Edwina Baskin-Bey; Taoufik Ouatas; Frank Perabo; De Phung; Mohammad Hirmand; Matthew R Smith Journal: Lancet Oncol Date: 2014-04-14 Impact factor: 41.316
Authors: Johanna I Kiiski; Liisa M Pelttari; Sofia Khan; Edda S Freysteinsdottir; Inga Reynisdottir; Steven N Hart; Hermela Shimelis; Sara Vilske; Anne Kallioniemi; Johanna Schleutker; Arto Leminen; Ralf Bützow; Carl Blomqvist; Rosa B Barkardottir; Fergus J Couch; Kristiina Aittomäki; Heli Nevanlinna Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Jeffrey N Weitzel; Elizabeth C Chao; Bita Nehoray; Lily R Van Tongeren; Holly LaDuca; Kathleen R Blazer; Thomas Slavin; D A B M D Facmg; Tina Pesaran; Christina Rybak; Ilana Solomon; Mariana Niell-Swiller; Jill S Dolinsky; Danielle Castillo; Aaron Elliott; Chia-Ling Gau; Virginia Speare; Kory Jasperson Journal: Genet Med Date: 2017-11-30 Impact factor: 8.822
Authors: Chen Wang; Jared M Evans; Aditya V Bhagwate; Naresh Prodduturi; Vivekananda Sarangi; Mridu Middha; Hugues Sicotte; Peter T Vedell; Steven N Hart; Gavin R Oliver; Jean-Pierre A Kocher; Matthew J Maurer; Anne J Novak; Susan L Slager; James R Cerhan; Yan W Asmann Journal: Bioinformatics Date: 2014-05-29 Impact factor: 6.937
Authors: Melissa J Landrum; Jennifer M Lee; Mark Benson; Garth Brown; Chen Chao; Shanmuga Chitipiralla; Baoshan Gu; Jennifer Hart; Douglas Hoffman; Jeffrey Hoover; Wonhee Jang; Kenneth Katz; Michael Ovetsky; George Riley; Amanjeev Sethi; Ray Tully; Ricardo Villamarin-Salomon; Wendy Rubinstein; Donna R Maglott Journal: Nucleic Acids Res Date: 2015-11-17 Impact factor: 16.971
Authors: Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch Journal: J Clin Oncol Date: 2021-10-21 Impact factor: 44.544
Authors: Anna Plym; Miklós Dióssy; Zoltan Szallasi; Oliver Sartor; Jonathan Silberstein; Isaac J Powell; Timothy R Rebbeck; Kathryn L Penney; Lorelei A Mucci; Mark M Pomerantz; Adam S Kibel Journal: JNCI Cancer Spectr Date: 2021-12-27
Authors: Daniel J Lee; Ryan Hausler; Anh N Le; Gregory Kelly; Jacquelyn Powers; James Ding; Emily Feld; Heena Desai; Casey Morrison; Abigail Doucette; Peter Gabriel; Regeneron Genetics Center; Renae L Judy; Joellen Weaver; Rachel Kember; Scott M Damrauer; Daniel J Rader; Susan M Domchek; Vivek Narayan; Lauren E Schwartz; Kara N Maxwell Journal: Eur Urol Date: 2021-10-25 Impact factor: 24.267